Prof. Mattias Collin is the head of the Department of Clinical Sciences at Lund University. He obtained his PhD in Cell and Molecular Biology from Lund University, Sweden, in 2001. He did his postdoctoral training in Vincent A. Fischetti’s Laboratory at Rockefeller University in New York (2001–2004). Thereafter, he has been leading his research group at at the Division of Infection Medicine at Lund University. His research is focused on bacterial enzymatic modification of immunoglobulins through proteolysis and glycan hydrolysis. His group has described how such enzymes contribute to bacterial immune evasion during infections and also how these activities can be exploited as drugs against autoimmunity and as biotechnological tools to characterize and modify antibodies. He is also a member of the American Society for Microbiology and the New York Academy of Sciences.